nisoldipine has been researched along with Angor Pectoris in 50 studies
Nisoldipine: A dihydropyridine calcium channel antagonist that acts as a potent arterial vasodilator and antihypertensive agent. It is also effective in patients with cardiac failure and angina.
nisoldipine : A racemate consisting of equimolar amounts of (R)- and (S)-nisoldipine. A calcium channel blocker, it is used in the treatment of hypertension and angina pectoris.
methyl 2-methylpropyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate : A dihydropyridine that is 1,4-dihydropyridine which is substituted by methyl groups at positions 2 and 6, a methoxycarbonyl group at position 3, an o-nitrophenyl group at position 4, and an isobutoxycarbonyl group at position 5. The racemate, a calcium channel blocker, is used in the treatment of hypertension and angina pectoris.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The efficacy and safety of nisoldipine-extended release (ER) and amlodipine were compared in a 6-week multicenter, randomized, double-blind, double-dummy, parallel group, titration-to-effect trial in patients with stage 1 to 2 systemic hypertension (90 to 109 mm Hg diastolic blood pressure [BP]) and chronic stable angina pectoris." | 9.10 | Comparison of effects of nisoldipine-extended release and amlodipine in patients with systemic hypertension and chronic stable angina pectoris. ( Bittar, N; Cooper-DeHoff, RM; Hutchinson, HG; Koren, M; Michelson, EL; Minkwitz, MC; Pepine, CJ; Thadani, U; Weiss, RJ, 2003) |
| "In 33 patients with stable angina pectoris, nisoldipine was tested (10 mg daily) in a randomized, double-blind, placebo-controlled study." | 9.08 | Antianginal and anti-ischemic efficacy of nisoldipine in stable angina pectoris: a randomized, double-blind, placebo-controlled trial. ( Chen, YH; Liu, RC; Wang, SP, 1996) |
| " Fifteen male patients with stable angina pectoris treated with atenolol were studied after undergoing routine cardiac catheterisation." | 9.07 | A comparison of the acute haemodynamic effects of nisoldipine and nifedipine during treatment with atenolol in patients with coronary artery disease. ( Dawkins, KD; Donaldson, KM; Waller, DG, 1993) |
| "5, 5, and 10 mg nisoldipine twice a day was not superior to placebo therapy in treating patients with angina pectoris, and the 10-mg-b." | 9.07 | Double-blind, dose-response, placebo-controlled multicenter study of nisoldipine. A new second-generation calcium channel blocker in angina pectoris. ( Bittar, N; Chaitman, B; DiBianco, R; Glasser, S; Miller, AB; Montoro, R; Schulman, P; Stahl, A; Thadani, U; Zellner, SR, 1991) |
| "The duration and extent of antianginal effects of nisoldipine, a dihydropyridine calcium antagonist, were assessed in 178 patients with chronic stable angina pectoris." | 9.07 | Usefulness of oral nisoldipine for stable angina pectoris. The Nisoldipine Multicenter Angina Study Group. ( Frishman, WH; Heiman, M, 1991) |
| "In order to evaluate the benefits of a calcium-antagonist medium-term treatment, 20 patients with effort stable angina pectoris were treated with nisoldipine in comparison to diltiazem." | 9.07 | [Comparison of nisoldipine and diltiazem in the treatment of effort angina pectoris]. ( Cicatiello, AM; de Caprio, L; De Rosa, ML; di Palma, A; Lombardi, L; Pandolfi, E; Rengo, F; Santamaria, F; Sestito, M; Voza, A, 1994) |
| "The acute haemodynamic effects of intravenous nisoldipine and hydralazine were compared in nine patients with heart failure." | 9.06 | Comparative haemodynamic effects of intravenous nisoldipine and hydralazine in congestive heart failure. ( Angel, ME; Haitas, B; Meyer, TE; Reef, E, 1990) |
| "The effects of the long-acting dihydropyridine calcium antagonist nisoldipine coat core (CC) have been investigated in > 3,500 patients with angina pectoris, hypertension, and ischemic ventricular dysfunction." | 8.79 | Efficacy and safety of nisoldipine coat core in the management of angina pectoris, systemic hypertension, and ischemic ventricular dysfunction. ( Lewis, BS, 1995) |
| "The effects of the calcium antagonists nicardipine and nisoldipine on left ventricular (LV) metabolism were analyzed in 32 patients with angina pectoris." | 7.67 | Effects of nicardipine and nisoldipine on myocardial metabolism, coronary blood flow and oxygen supply in angina pectoris. ( Charlier, AA; Pouleur, H; Rousseau, MF; Van den Berghe, G; Van Hoof, F; Vincent, MF, 1984) |
| "In atenolol-treated patients with severe effort angina pectoris, nifedipine 20 mg tid improved exercise capacity, while nisoldipine 20 mg once daily did not have a similar effect." | 6.67 | Nisoldipine tablets once daily versus nifedipine capsules three times daily in patients with stable effort angina pectoris pretreated with atenolol. ( Kantor, M; Pedersen, TR, 1990) |
| " This trial confirms that immediate-release nisoldipine when added to existent beta-blocker therapy is an active antianginal and anti-ischemic agent, but that the immediate-release formulation loses its antianginal effect at the end of its dosing interval (9 to 14 hours)." | 6.67 | Antianginal and anti-ischemic efficacy of immediate-release nisoldipine in chronic stable angina pectoris. ( Bittar, N; Glasser, SP; Katz, R; Labreche, DG; Schulman, P; Singh, B, 1994) |
| "Nisoldipine is a second-generation dihydropyridine calcium channel blocker (CCB)." | 6.40 | Nisoldipine CC: efficacy and tolerability in hypertension and ischemic heart disease. ( Fodor, JG, 1997) |
| "Nisoldipine is a second-generation dihydropyridine calcium antagonist that has been extensively studied as an antianginal and antihypertensive agent." | 6.39 | Nisoldipine coat core as concomitant therapy in chronic stable angina pectoris. ( Glasser, SP, 1995) |
| "Nisoldipine is an orally administered calcium entry blocking drug structurally related to nifedipine." | 6.37 | Nisoldipine. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of angina pectoris, hypertension and related cardiovascular disorders. ( Friedel, HA; Sorkin, EM, 1988) |
| "The efficacy and safety of nisoldipine-extended release (ER) and amlodipine were compared in a 6-week multicenter, randomized, double-blind, double-dummy, parallel group, titration-to-effect trial in patients with stage 1 to 2 systemic hypertension (90 to 109 mm Hg diastolic blood pressure [BP]) and chronic stable angina pectoris." | 5.10 | Comparison of effects of nisoldipine-extended release and amlodipine in patients with systemic hypertension and chronic stable angina pectoris. ( Bittar, N; Cooper-DeHoff, RM; Hutchinson, HG; Koren, M; Michelson, EL; Minkwitz, MC; Pepine, CJ; Thadani, U; Weiss, RJ, 2003) |
| "In 33 patients with stable angina pectoris, nisoldipine was tested (10 mg daily) in a randomized, double-blind, placebo-controlled study." | 5.08 | Antianginal and anti-ischemic efficacy of nisoldipine in stable angina pectoris: a randomized, double-blind, placebo-controlled trial. ( Chen, YH; Liu, RC; Wang, SP, 1996) |
| " Fifteen male patients with stable angina pectoris treated with atenolol were studied after undergoing routine cardiac catheterisation." | 5.07 | A comparison of the acute haemodynamic effects of nisoldipine and nifedipine during treatment with atenolol in patients with coronary artery disease. ( Dawkins, KD; Donaldson, KM; Waller, DG, 1993) |
| "The aim of this study was to investigate the anti-ischemic and antianginal activity and the duration of the new dihydropyridine calcium blocker nisoldipine (NIS) in patients with stable angina pectoris." | 5.07 | Effect of calcium antagonists on exercise tests. ( Cherchi, A; Cherchi, PA; Lai, C; Lai, G; Onnis, E; Solinas, R, 1992) |
| "The duration and extent of antianginal effects of nisoldipine, a dihydropyridine calcium antagonist, were assessed in 178 patients with chronic stable angina pectoris." | 5.07 | Usefulness of oral nisoldipine for stable angina pectoris. The Nisoldipine Multicenter Angina Study Group. ( Frishman, WH; Heiman, M, 1991) |
| "5, 5, and 10 mg nisoldipine twice a day was not superior to placebo therapy in treating patients with angina pectoris, and the 10-mg-b." | 5.07 | Double-blind, dose-response, placebo-controlled multicenter study of nisoldipine. A new second-generation calcium channel blocker in angina pectoris. ( Bittar, N; Chaitman, B; DiBianco, R; Glasser, S; Miller, AB; Montoro, R; Schulman, P; Stahl, A; Thadani, U; Zellner, SR, 1991) |
| "The effects of the addition of slow-release nifedipine 20 mg twice daily and nisoldipine 10 mg twice daily to atenolol monotherapy were compared in a double-blind placebo-controlled study of 24 patients with chronic stable angina pectoris." | 5.07 | A comparison of nisoldipine and nifedipine, in combination with atenolol, in the management of myocardial ischaemia. ( Dawkins, KD; Donaldson, KM; Waller, DG, 1993) |
| "In order to evaluate the benefits of a calcium-antagonist medium-term treatment, 20 patients with effort stable angina pectoris were treated with nisoldipine in comparison to diltiazem." | 5.07 | [Comparison of nisoldipine and diltiazem in the treatment of effort angina pectoris]. ( Cicatiello, AM; de Caprio, L; De Rosa, ML; di Palma, A; Lombardi, L; Pandolfi, E; Rengo, F; Santamaria, F; Sestito, M; Voza, A, 1994) |
| "We studied the short-term effects of oral administration of nisoldipine (10 mg) and propranolol (80 mg) alone and in combination in 14 patients with chronic exertional angina pectoris in a double-blind, randomized, cross-over study." | 5.06 | Acute effects of nisoldipine, propranolol, and their combination in patients with chronic stable angina: a double-blind, randomized, cross-over, placebo-controlled study. ( Abete, P; Acanfora, D; Cicatiello, AM; Covelluzzi, F; De Caprio, L; Gallucci, F; Papa, M; Rengo, F, 1990) |
| "The acute haemodynamic effects of intravenous nisoldipine and hydralazine were compared in nine patients with heart failure." | 5.06 | Comparative haemodynamic effects of intravenous nisoldipine and hydralazine in congestive heart failure. ( Angel, ME; Haitas, B; Meyer, TE; Reef, E, 1990) |
| "To investigate the mechanism of antianginal action of the calcium channel blocker nisoldipine and to determine the reproducibility of the clinical and hemodynamic events induced by supine leg exercise, 30 patients with stable effort angina pectoris were studied." | 5.06 | Hemodynamic mechanisms of antianginal action of calcium channel blocker nisoldipine in dynamic exercise-induced angina. ( Iwase, M; Kamihara, S; Koide, M; Matsunami, T; Miyahara, T; Saito, H; Takeuchi, J; Watanabe, M; Yokota, M, 1990) |
| "The effects of the long-acting dihydropyridine calcium antagonist nisoldipine coat core (CC) have been investigated in > 3,500 patients with angina pectoris, hypertension, and ischemic ventricular dysfunction." | 4.79 | Efficacy and safety of nisoldipine coat core in the management of angina pectoris, systemic hypertension, and ischemic ventricular dysfunction. ( Lewis, BS, 1995) |
| "The purpose of this study was to determine the response of plasma levels of endothelin-1 (ET-1) to dynamic exercise in patients with coronary artery disease and chronic stable angina pectoris and positive exercise tolerance test, before and after treatment with the calcium antagonist nisoldipine (20 mg/day buccally for 7 days)." | 3.69 | Plasma endothelin-1 concentrations in patients with coronary artery disease during stress test before and after nisoldipine administration. ( Barillà, F; Campa, PP; Cerci, S; Coassin, S; D'Ambrosio, C; De Ciocchis, A; Letizia, C; Mastroianni, MA; Scavo, D, 1996) |
| "To evaluate the effects of antianginal agents on the correlation between rate-pressure product and myocardial oxygen uptake, multistage supine leg exercise tests were performed by 21 patients with stable effort-induced angina pectoris before and after administration of antianginal drugs (a calcium channel blocker of the dihydropyridine class [10 mg of nisoldipine orally] in 11 patients and a beta-blocker [0." | 3.68 | Effect of antianginal agents on the relationship between rate-pressure product and myocardial oxygen uptake. ( Kodama, Y; Matsunami, T; Miyahara, T; Saito, H; Sobue, T; Yokota, M, 1993) |
| "The effects of the calcium antagonists nicardipine and nisoldipine on left ventricular (LV) metabolism were analyzed in 32 patients with angina pectoris." | 3.67 | Effects of nicardipine and nisoldipine on myocardial metabolism, coronary blood flow and oxygen supply in angina pectoris. ( Charlier, AA; Pouleur, H; Rousseau, MF; Van den Berghe, G; Van Hoof, F; Vincent, MF, 1984) |
| " Among 15 patients with coronary artery disease who had been treated with nisoldipine, onset of severe unstable angina was observed in 2 and evolution of acute myocardial infarction in 1 patient after abrupt withdrawal of nisoldipine therapy." | 3.67 | Calcium-blocker withdrawal phenomenon: increase in affinity of alpha 2 adrenoceptors for agonist as a potential mechanism. ( Lopez, LM; Mehta, J, 1986) |
| " This trial confirms that immediate-release nisoldipine when added to existent beta-blocker therapy is an active antianginal and anti-ischemic agent, but that the immediate-release formulation loses its antianginal effect at the end of its dosing interval (9 to 14 hours)." | 2.67 | Antianginal and anti-ischemic efficacy of immediate-release nisoldipine in chronic stable angina pectoris. ( Bittar, N; Glasser, SP; Katz, R; Labreche, DG; Schulman, P; Singh, B, 1994) |
| "In atenolol-treated patients with severe effort angina pectoris, nifedipine 20 mg tid improved exercise capacity, while nisoldipine 20 mg once daily did not have a similar effect." | 2.67 | Nisoldipine tablets once daily versus nifedipine capsules three times daily in patients with stable effort angina pectoris pretreated with atenolol. ( Kantor, M; Pedersen, TR, 1990) |
| "A double-blind, placebo-controlled study was performed to assess whether a new calcium antagonist, nisoldipine, in doses of either 5 mg or 10 mg daily, in combination with beta-adrenergic-blocking drugs (combination therapy) was more effective than beta-adrenergic-blocking drugs alone (single therapy) in the treatment of chronic stable angina." | 2.66 | Efficacy of nisoldipine combined with beta-adrenergic-blocking drugs in the treatment of chronic stable angina. ( Banim, SO; Creamer, JE; O'Keefe, JC, 1987) |
| "Nisoldipine is an effective antianginal agent which performs well in comparison to nifedipine." | 2.66 | Comparative antianginal effects of nisoldipine and nifedipine in patients with chronic stable angina. ( Chaitman, BR; Crean, PA; Lam, J; Waters, DD, 1987) |
| "Nisoldipine is a second-generation dihydropyridine calcium channel blocker (CCB)." | 2.40 | Nisoldipine CC: efficacy and tolerability in hypertension and ischemic heart disease. ( Fodor, JG, 1997) |
| "Nisoldipine is a second-generation dihydropyridine calcium antagonist that has been extensively studied as an antianginal and antihypertensive agent." | 2.39 | Nisoldipine coat core as concomitant therapy in chronic stable angina pectoris. ( Glasser, SP, 1995) |
| " The most optimal dosage regimen has not been established in clinical trials." | 2.38 | Nisoldipine: a new dihydropyridine calcium-channel blocker. ( Frishman, W; Heiman, M; Mitchell, J, 1993) |
| "Nisoldipine is an orally administered calcium entry blocking drug structurally related to nifedipine." | 2.37 | Nisoldipine. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of angina pectoris, hypertension and related cardiovascular disorders. ( Friedel, HA; Sorkin, EM, 1988) |
| "Thus nisoldipine acts as a peripheral dilating agent, decreasing arteriolar tone and, possible, venous tone, and increasing left ventricular muscle distensibility." | 1.28 | Haemodynamic effects of nisoldipine by oral route. ( Boffa, GM; Calvanese, A; Chioin, R; Isabella, G; Ramondo, A; Razzolini, R, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 15 (30.00) | 18.7374 |
| 1990's | 34 (68.00) | 18.2507 |
| 2000's | 1 (2.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Pepine, CJ | 1 |
| Cooper-DeHoff, RM | 1 |
| Weiss, RJ | 1 |
| Koren, M | 1 |
| Bittar, N | 4 |
| Thadani, U | 2 |
| Minkwitz, MC | 1 |
| Michelson, EL | 1 |
| Hutchinson, HG | 1 |
| Donaldson, KM | 2 |
| Dawkins, KD | 2 |
| Waller, DG | 2 |
| Brügmann, U | 1 |
| Blasini, R | 1 |
| Rudolph, W | 1 |
| Hess, OM | 1 |
| Krayenbühl, HP | 1 |
| Rousseau, MF | 1 |
| Vincent, MF | 1 |
| Van Hoof, F | 1 |
| Van den Berghe, G | 1 |
| Charlier, AA | 1 |
| Pouleur, H | 1 |
| Smith, FB | 1 |
| Helms, RW | 1 |
| Lewis, BS | 1 |
| Glasser, SP | 3 |
| Ogawa, H | 1 |
| Yasue, H | 1 |
| Nakamura, N | 1 |
| Fujii, H | 1 |
| Miyagi, H | 1 |
| Kikuta, K | 1 |
| Labreche, DG | 1 |
| Singh, B | 1 |
| Katz, R | 1 |
| Schulman, P | 2 |
| de Caprio, L | 3 |
| Sestito, M | 1 |
| Pandolfi, E | 1 |
| Santamaria, F | 1 |
| di Palma, A | 1 |
| Lombardi, L | 1 |
| Voza, A | 1 |
| De Rosa, ML | 1 |
| Cicatiello, AM | 2 |
| Rengo, F | 3 |
| Grönefeld, G | 1 |
| Bernhardt, J | 1 |
| Schneider, W | 1 |
| Kodama, Y | 1 |
| Yokota, M | 2 |
| Miyahara, T | 2 |
| Matsunami, T | 2 |
| Sobue, T | 1 |
| Saito, H | 2 |
| Sheiban, I | 1 |
| Tonni, S | 1 |
| Benussi, P | 1 |
| Marini, A | 1 |
| Trevi, GP | 1 |
| Mitchell, J | 1 |
| Frishman, W | 1 |
| Heiman, M | 2 |
| Ripa, S | 1 |
| Garland, WT | 1 |
| Weiss, R | 1 |
| Nademanee, K | 1 |
| Singh, S | 1 |
| Mori, T | 1 |
| Ishigai, Y | 1 |
| Fukuzawa, A | 1 |
| Chiba, K | 1 |
| Shibano, T | 1 |
| Letizia, C | 1 |
| Barillà, F | 1 |
| Cerci, S | 1 |
| De Ciocchis, A | 1 |
| Coassin, S | 1 |
| Mastroianni, MA | 1 |
| D'Ambrosio, C | 1 |
| Campa, PP | 1 |
| Scavo, D | 1 |
| Chen, YH | 1 |
| Liu, RC | 1 |
| Wang, SP | 1 |
| Fodor, JG | 1 |
| Gheorghiade, M | 1 |
| Lai, C | 1 |
| Cherchi, A | 1 |
| Onnis, E | 1 |
| Solinas, R | 1 |
| Lai, G | 1 |
| Cherchi, PA | 1 |
| Eber, B | 1 |
| Schumacher, M | 1 |
| Zweiker, R | 1 |
| Pokan, R | 1 |
| Klein, W | 1 |
| Fresco, C | 1 |
| Papa, M | 2 |
| Acanfora, D | 2 |
| Abete, P | 1 |
| Gallucci, F | 2 |
| Covelluzzi, F | 2 |
| Krivonkin, KIu | 1 |
| Belousov, IuB | 1 |
| Frishman, WH | 1 |
| Razzolini, R | 1 |
| Boffa, GM | 1 |
| Calvanese, A | 1 |
| Isabella, G | 1 |
| Ramondo, A | 1 |
| Chioin, R | 1 |
| Zellner, SR | 1 |
| Glasser, S | 1 |
| Montoro, R | 1 |
| Miller, AB | 1 |
| Chaitman, B | 1 |
| Stahl, A | 1 |
| DiBianco, R | 1 |
| Waters, D | 1 |
| Godfraind, T | 1 |
| Kilz, U | 1 |
| Knaup, G | 1 |
| Petretta, M | 1 |
| Morgano, G | 1 |
| Arrichiello, P | 1 |
| Breglio, R | 1 |
| Lanzillo, T | 1 |
| Mazza, F | 1 |
| Bonaduce, D | 1 |
| Pedersen, TR | 1 |
| Kantor, M | 1 |
| Haitas, B | 1 |
| Meyer, TE | 1 |
| Angel, ME | 1 |
| Reef, E | 1 |
| Iwase, M | 1 |
| Watanabe, M | 1 |
| Kamihara, S | 1 |
| Koide, M | 1 |
| Takeuchi, J | 1 |
| Kimball, BP | 1 |
| Watson, KR | 1 |
| Bui, S | 1 |
| Frankel, D | 1 |
| Gansser, RE | 1 |
| Bachmann, KF | 1 |
| O'Keefe, JC | 1 |
| Creamer, JE | 1 |
| Banim, SO | 1 |
| Ram, J | 1 |
| Freedman, SB | 1 |
| Ogasawara, S | 1 |
| Thomson, A | 1 |
| Kelly, DT | 1 |
| Mehta, J | 1 |
| Lopez, LM | 2 |
| Friedel, HA | 1 |
| Sorkin, EM | 1 |
| Leosco, D | 1 |
| Borgnino, C | 1 |
| Cicatiello, M | 1 |
| Cosentino, F | 1 |
| Singer, M | 1 |
| Trotman, IF | 1 |
| Crean, PA | 1 |
| Waters, DD | 2 |
| Lam, J | 2 |
| Chaitman, BR | 2 |
| Lagioia, R | 1 |
| Scrutinio, D | 1 |
| Mangini, SG | 1 |
| Accettura, D | 1 |
| Mastropasqua, F | 1 |
| Caporale, R | 1 |
| Caiati, C | 1 |
| Zanna, D | 1 |
| Chiddo, A | 1 |
| Rizzon, P | 1 |
| Silke, B | 1 |
| Verma, SP | 1 |
| Midtbo, KA | 1 |
| Müller, P | 1 |
| Frais, MA | 1 |
| Reynolds, G | 1 |
| Taylor, SH | 1 |
| Crean, P | 1 |
| Blum, R | 1 |
| Rubin, MR | 1 |
| Holland, JP | 1 |
| Mehta, JL | 1 |
7 reviews available for nisoldipine and Angor Pectoris
| Article | Year |
|---|---|
Efficacy and safety of nisoldipine coat core in the management of angina pectoris, systemic hypertension, and ischemic ventricular dysfunction.
Topics: Angina Pectoris; Delayed-Action Preparations; Humans; Hypertension; Myocardial Infarction; Nisoldipi | 1995 |
Nisoldipine coat core as concomitant therapy in chronic stable angina pectoris.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Chronic Disease; Delayed-Action Preparations; Drug The | 1995 |
Nisoldipine: a new dihydropyridine calcium-channel blocker.
Topics: Angina Pectoris; Cardiovascular Diseases; Heart Rate; Hemodynamics; Humans; Hypertension; Nisoldipin | 1993 |
Nisoldipine CC: efficacy and tolerability in hypertension and ischemic heart disease.
Topics: Aging; Angina Pectoris; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Delayed-A | 1997 |
[Nisoldipine in comparison with long-term nitrates].
Topics: Angina Pectoris; Animals; Coronary Circulation; Coronary Disease; Coronary Vasospasm; Humans; Myocar | 1992 |
[Clinical pharmacology of nisoldipine, a new calcium antagonist].
Topics: Angina Pectoris; Animals; Cardiovascular Diseases; Drug Interactions; Humans; Hypertension; Nisoldip | 1991 |
Nisoldipine. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of angina pectoris, hypertension and related cardiovascular disorders.
Topics: Angina Pectoris; Calcium Channel Blockers; Cardiovascular Diseases; Humans; Hypertension; Nifedipine | 1988 |
26 trials available for nisoldipine and Angor Pectoris
| Article | Year |
|---|---|
Comparison of effects of nisoldipine-extended release and amlodipine in patients with systemic hypertension and chronic stable angina pectoris.
Topics: Amlodipine; Angina Pectoris; Calcium Channel Blockers; Delayed-Action Preparations; Double-Blind Met | 2003 |
A comparison of the acute haemodynamic effects of nisoldipine and nifedipine during treatment with atenolol in patients with coronary artery disease.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angina Pectoris; Atenolol; Blood Pressure; Calcium Channel | 1993 |
[Comparison of the anti-ischemia effect of nisoldipine and verapamil. Double-blind randomized cross-over and placebo-controlled acute and long-term study].
Topics: Angina Pectoris; Blood Pressure; Calcium Channel Blockers; Clinical Trials as Topic; Coronary Diseas | 1984 |
Comparison of efficacy of nisoldipine, metoprolol, and isosorbide dinitrate in patients with stable exertional angina: a randomized, cross-over, placebo-controlled study.
Topics: Administration, Oral; Aged; Angina Pectoris; Blood Pressure; Cross-Over Studies; Exercise Test; Exer | 1995 |
Antianginal and anti-ischemic efficacy of immediate-release nisoldipine in chronic stable angina pectoris.
Topics: Adrenergic beta-Antagonists; Adult; Angina Pectoris; Blood Pressure; Chronic Disease; Double-Blind M | 1994 |
[Comparison of nisoldipine and diltiazem in the treatment of effort angina pectoris].
Topics: Administration, Oral; Adult; Angina Pectoris; Diltiazem; Double-Blind Method; Electrocardiography; E | 1994 |
[Dose-response relationship of nisoldipine in patients with stable angina pectoris and stress-induced myocardial ischemia].
Topics: Adult; Aged; Angina Pectoris; Cardiac Catheterization; Coronary Disease; Delayed-Action Preparations | 1993 |
Left ventricular dysfunction following transient ischaemia induced by transluminal coronary angioplasty. Beneficial effects of calcium antagonists against post-ischaemic myocardial stunning.
Topics: Adult; Aged; Angina Pectoris; Angioplasty, Balloon, Coronary; Coronary Circulation; Coronary Disease | 1993 |
A comparison of nisoldipine and nifedipine, in combination with atenolol, in the management of myocardial ischaemia.
Topics: Adult; Aged; Angina Pectoris; Atenolol; Delayed-Action Preparations; Dose-Response Relationship, Dru | 1993 |
Antianginal and antiischemic efficacy of monotherapy extended-release nisoldipine (Coat Core) in chronic stable angina.
Topics: Adult; Aged; Aged, 80 and over; Angina Pectoris; Calcium Channel Blockers; Chronic Disease; Delayed- | 1995 |
Antianginal and anti-ischemic efficacy of nisoldipine in stable angina pectoris: a randomized, double-blind, placebo-controlled trial.
Topics: Aged; Angina Pectoris; Blood Pressure; Calcium Channel Blockers; Double-Blind Method; Drug Administr | 1996 |
Effect of calcium antagonists on exercise tests.
Topics: Adult; Aged; Analysis of Variance; Angina Pectoris; Blood Pressure; Double-Blind Method; Electrocard | 1992 |
Acute effects of nisoldipine, propranolol, and their combination in patients with chronic stable angina: a double-blind, randomized, cross-over, placebo-controlled study.
Topics: Aged; Angina Pectoris; Double-Blind Method; Drug Therapy, Combination; Exercise Test; Female; Hemody | 1990 |
Usefulness of oral nisoldipine for stable angina pectoris. The Nisoldipine Multicenter Angina Study Group.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Angina Pectoris; Double-Blind Method; Electroc | 1991 |
Double-blind, dose-response, placebo-controlled multicenter study of nisoldipine. A new second-generation calcium channel blocker in angina pectoris.
Topics: Adult; Angina Pectoris; Blood Pressure; Dose-Response Relationship, Drug; Double-Blind Method; Exerc | 1991 |
[Nisoldipine in stable angina pectoris. Efficacy and tolerance in comparison with diltiazem].
Topics: Adult; Aged; Angina Pectoris; Diltiazem; Exercise Test; Female; Hemodynamics; Humans; Male; Middle A | 1991 |
[Nisoldipine in the therapy of stable exercise angina: evaluation of its efficacy in ergometric tests compared with propranolol].
Topics: Adult; Angina Pectoris; Coronary Circulation; Exercise; Exercise Test; Female; Humans; Male; Middle | 1990 |
Nisoldipine tablets once daily versus nifedipine capsules three times daily in patients with stable effort angina pectoris pretreated with atenolol.
Topics: Adult; Angina Pectoris; Atenolol; Blood Pressure; Capsules; Double-Blind Method; Drug Administration | 1990 |
Comparative haemodynamic effects of intravenous nisoldipine and hydralazine in congestive heart failure.
Topics: Adult; Aged; Angina Pectoris; Blood Pressure; Calcium Channel Blockers; Cardiac Output; Heart Failur | 1990 |
Hemodynamic mechanisms of antianginal action of calcium channel blocker nisoldipine in dynamic exercise-induced angina.
Topics: Adult; Aged; Angina Pectoris; Coronary Angiography; Coronary Circulation; Electrocardiography; Exerc | 1990 |
Efficacy of nisoldipine combined with beta-adrenergic-blocking drugs in the treatment of chronic stable angina.
Topics: Adrenergic beta-Antagonists; Aged; Angina Pectoris; Chronic Disease; Coronary Angiography; Double-Bl | 1987 |
[Acute effects of nisoldipine in patients with stable effort angina].
Topics: Angina Pectoris; Calcium Channel Blockers; Clinical Trials as Topic; Double-Blind Method; Exercise T | 1988 |
Use of exercise Doppler for non-invasive haemodynamic optimization of dose and identification of poor responders to an oral anti-anginal agent. A double-blind dose-finding study of nisoldipine.
Topics: Administration, Oral; Angina Pectoris; Aorta; Blood Flow Velocity; Calcium Channel Blockers; Clinica | 1988 |
Comparative antianginal effects of nisoldipine and nifedipine in patients with chronic stable angina.
Topics: Aged; Angina Pectoris; Calcium Channel Blockers; Chronic Disease; Clinical Trials as Topic; Double-B | 1987 |
A haemodynamic study of the effects of combined slow-calcium channel blockade (nisoldipine) and beta-blockade (metoprolol) in coronary heart disease.
Topics: Adult; Angina Pectoris; Calcium Channel Blockers; Coronary Disease; Drug Therapy, Combination; Hemod | 1986 |
A dose-ranging, placebo-controlled, double-blind trial of nisoldipine in effort angina: duration and extent of antianginal effects.
Topics: Aged; Angina Pectoris; Calcium Channel Blockers; Clinical Trials as Topic; Coronary Disease; Dose-Re | 1985 |
17 other studies available for nisoldipine and Angor Pectoris
| Article | Year |
|---|---|
[Antianginal effect of calcium antagonists, using nisoldipine as an example].
Topics: Angina Pectoris; Blood Pressure; Calcium Channel Blockers; Electrocardiography; Exercise Test; Heart | 1984 |
Effects of nicardipine and nisoldipine on myocardial metabolism, coronary blood flow and oxygen supply in angina pectoris.
Topics: Aged; Angina Pectoris; Calcium Channel Blockers; Coronary Circulation; Hemodynamics; Humans; Lactate | 1984 |
EM mixed model analysis of data from informatively censored normal distributions.
Topics: Algorithms; Angina Pectoris; Controlled Clinical Trials as Topic; Cross-Over Studies; Dose-Response | 1995 |
Effect of antianginal agents on the relationship between rate-pressure product and myocardial oxygen uptake.
Topics: Adult; Aged; Angina Pectoris; Blood Pressure; Coronary Angiography; Drug Evaluation; Electrocardiogr | 1993 |
Pharmacological profile of semotiadil fumarate, a novel calcium antagonist, in rat experimental angina model.
Topics: Acetylcholine; Angina Pectoris; Animals; Arginine Vasopressin; Calcium Channel Blockers; Coronary Ve | 1995 |
Plasma endothelin-1 concentrations in patients with coronary artery disease during stress test before and after nisoldipine administration.
Topics: Adult; Aged; Angina Pectoris; Calcium Channel Blockers; Coronary Disease; Endothelins; Exercise Test | 1996 |
Nisoldipine and myocardial infarction.
Topics: Angina Pectoris; Calcium Channel Blockers; Humans; Myocardial Ischemia; Nisoldipine | 1998 |
Efficacy of nisoldipine.
Topics: Angina Pectoris; Humans; Nisoldipine | 1992 |
Haemodynamic effects of nisoldipine by oral route.
Topics: Administration, Oral; Adult; Aged; Angina Pectoris; Blood Pressure; Cardiac Output; Hemodynamics; Hu | 1991 |
Proischemic complications of dihydropyridine calcium channel blockers.
Topics: Angina Pectoris; Coronary Disease; Coronary Vessels; Humans; Nisoldipine | 1991 |
Is the combination between beta-blockers and calcium antagonists appropriate in the management of angina pectoris?
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Calcium Channel Blockers; Drug Synergism; Drug Therapy | 1990 |
Preservation of left ventricular performance with reduced ischemic dysfunction by intravenous nisoldipine.
Topics: Adult; Aged; Angina Pectoris; Coronary Disease; Female; Heart; Humans; Infusions, Intravenous; Injec | 1990 |
Dilatation of epicardial coronary arteries and attenuation of provoked coronary vasoconstriction by nisoldipine.
Topics: Adult; Aged; Angina Pectoris; Coronary Angiography; Coronary Vessels; Ergonovine; Female; Hemodynami | 1989 |
Effects of nisoldipine on systemic and leg blood flow, oxygen transport and metabolism, and hemodynamics during exercise in effort angina pectoris.
Topics: Adult; Angina Pectoris; Cardiac Output; Heart Rate; Hemodynamics; Humans; Lactates; Lactic Acid; Leg | 1989 |
Calcium-blocker withdrawal phenomenon: increase in affinity of alpha 2 adrenoceptors for agonist as a potential mechanism.
Topics: Adult; Angina Pectoris; Blood Platelets; Calcium Channel Blockers; Coronary Disease; Epinephrine; Hu | 1986 |
[Acute effects of various doses of nisoldipine in stable exertional angina].
Topics: Adult; Aged; Angina Pectoris; Dose-Response Relationship, Drug; Exercise Test; Female; Humans; Male; | 1987 |
Improvement in exercise performance with nisoldipine, a new second-generation calcium blocker, in stable angina patients.
Topics: Adult; Aged; Angina Pectoris; Blood Pressure; Calcium Channel Blockers; Dose-Response Relationship, | 1985 |